Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$31.56 USD
-1.11 (-3.40%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $31.53 -0.03 (-0.10%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CORT 31.56 -1.11(-3.40%)
Will CORT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CORT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CORT
Corcept (CORT) Shares Rise 20% in Three Months: Here's Why
Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?
CORT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?
Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report?
Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?
Other News for CORT
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
7 Biotech Stocks to Boost Your Portfolio to Peak Health
Interesting CORT Put And Call Options For February 2025
Corcept Therapeutics (CORT) Gets a Buy from Truist Financial
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions